|
Commemorating
the 25th Anniversary of the False Claims Act
Download
the 25th Anniversary Brochure prepared by
the Taxpayers Against Fraud Education Fund (PDF)
ELAN
& EISAI NEWS
FEB.
28, 2011: Elan Convicted Over Marketing of Zonegran
Elan
pleads guilty to misdemeanor violation of federal law in the
marketing of epilepsy drug.
DEC.
15, 2010: Elan & Eisai Whistleblower Cases Settle for
$203 Million and $11 Million
Law
firms assist successful prosecution of off-label marketing
cases. The case involved allegations of improper "off-label"
marketing of the anti-seizure drug Zonegran, first by Irish
pharmaceutical manufacturer Elan Corp., then later by Japanese
pharmaceutical company Eisai, Inc., which bought the rights
to the drug from Elan in 2004.
FOREST
LABORATORIES FRAUD NEWS
MAR.
2, 2011: Forest Pharmaceuticals Sentenced to Pay $164 Million
for Criminal Violations
Forest
Pharmaceuticals Inc. was sentenced today by U.S. District
Judge Nancy Gertner to pay a criminal fine of $150 million
and forfeit assets of $14 million following the companys
guilty plea in November 2010 to one felony count of obstructing
justice, one misdemeanor count of distributing an unapproved
new drug in interstate commerce and one misdemeanor count
of distributing a misbranded drug in interstate commerce.
SEPT.
15, 2010: Forest paying $313 million in government probe
Forest
Laboratories Inc. said Wednesday it finalized a deal for $313
million with the Justice Department in fines and a settlement
over allegations it gave kickbacks to doctors who prescribed
its antidepressants.
RELATED
NEWS COVERAGE
View
latest news stories and analysis on this topic as aggregated
by Google News
PREVIOUS
ANNOUNCEMENTS
Judge
Nathaniel Gorton denied Forest's motion to dismiss relator's
employment claim.
Read
the United States' DOJ Announcement. (PDF)
A Complaint
was unsealed today in U.S. District Court in Massachusetts
against a New York pharmaceutical company for alleged False
Claims Act violations arising from the companys marketing
the drugs Celexa and Lexapro for unapproved pediatric use
and for paying kickbacks to induce physicians to prescribe
the drugs.
Complete
Press Release. (PDF)
Read
the United States' Complaint. (PDF)
AMGEN
ARANESP KICKBACK NEWS
Boston
attorneys Suzanne E. Durrell, Robert M. Thomas, Jr., and Rory
Delaney, and Los Angeles attorneys Charles F. Kester and Lawrence
M. Isenberg of the law firm Kester & Isenberg, announced
today the filing of an amended complaint against biotechnology
company Amgen Inc. and others, in a case pending before United
District Court Judge William G. Young in Boston. The amended
complaint, filed pursuant to federal and state False Claims
Acts by Relator Kassie Westmoreland, a former Amgen employee,
is filed the same day as a consolidated complaint in intervention
brought by fifteen state Attorney General offices. These state
plaintiffs recently filed notices of intervention in Ms. Westmoreland's
lawsuit.
Related
Press Release | (PDF)
NEW:
4th Amended Complaint (PDF)
Amended Complaint (PDF)
| Multistate
Amgen Complaint (PDF)
RELATED
STORIES
Amgen
Execs Take The 5th Over Alleged Kickbacks
Pharmalot
5
Amgen Execs Plead the Fifth on Alleged Kickbacks Described
in Spreadsheet
BNet
Amgen
sued by California and 14 other states over anemia drug
Los Angeles Times
Amgen
Is Accused of Illegal Kickbacks
New York Times
View
latest news stories and blog analysis on this topic as aggregated
by Google News
St.
Jude Medical
The
U.S. Justice Department said it wants to intervene in a lawsuit
against St. Jude Medical, Inc. in which a former worker accused
the heart-device maker of using medical studies to pay kickbacks
and boost product usage.
RELATED
STORIES
US
To Intervene In Alleged St Jude Kickback Case
NASDAQ, Dow Jones Newswire
U.S.
Can Join St. Jude Medical False Claims Case
Bloomberg Businessweek
$2.3
BILLION PFIZER SETTLEMENT NEWS
Pfizer
Inc. will pay approximately $2.3 billion dollars to settle
claims it misbranded one of its pain killer drugs, promoted
the off label use of numerous drugs, and paid kickbacks to
doctors to induce or reward the prescription of Pfizer drugs.
Boston attorneys Suzanne E. Durrell, Robert M. Thomas, Jr.
and Rory Delaney represent one of the whistleblowers, Blair
Collins, who brought kickback allegations regarding the drugs
Lipitor, Norvasc, Viagra, Zithromax, and Zyrtec, and whose
information helped form the basis for today's settlement.
Read
the Pfizer Settlement Press Release | (PDF)
Official
DOJ Pfizer Announcement
RELATED
STORIES
VIDEO:
Drug maker Pfizer to pay record $2.3 billion penalty over
promotions
(NECN: Washington) - Pfizer Inc., the world's largest drug
maker, will pay a record $2.3 billion civil and criminal penalty
over unlawful prescription drug promotions. The...
Pfizer
To Pay $2.3B To Settle Case On Drug Marketing - DOJ
Wall Street Journal - WASHINGTON (Dow Jones)--Pfizer Inc.
(PFE) has agreed to pay $2.3 billion to settle charges that
it illegally ...
Pfizer
Pays $2.3 Billion to Settle Marketing Case
New York Times
Pfizer
settles drug-promotion case for $2.3 billion
MarketWatch
Pfizer,
Subsidiary to Pay $2.3B in Health-Care Fraud Case
Washington Post
Pfizer
to pay record $2.3B penalty over promotions
Boston Globe
View
latest news stories and blog analysis on this topic as aggregated
by Google News
BIG
DIG FRAUD NEWS
Big
Dig Whistleblower Dan Johnston Pleased with 10-9 Concrete
Fraud SettlementEncourages Others to Come Forward
Read
the press release. (Or, download PDF)
(PHOTO:
JOSH REYNOLDS FOR THE BOSTON GLOBE, HOSTED ON
BOSTON.COM)
RELATED
STORIES
Big
Dig payment for fraud at $50m
Big
Dig firm seen in $42m settlement--Supplier linked to faulty
concrete
Complete
story on Boston Globe site. | Related
Globe story | Newswire
Coverage
JANUARY
2008 NEWS
DOJ
& Mass. AG: Big Dig Management Consultant and Designers
to Pay $450 Million
Read
the official announcement.
Boston
Globe Editorial: Shoddy work, big settlement
Read
the article.
»
Read all stories on this topic
(Generates
customized Google news search results in a new window.)
|